Viewing Study NCT04579133


Ignite Creation Date: 2025-12-25 @ 2:42 AM
Ignite Modification Date: 2026-03-11 @ 9:10 PM
Study NCT ID: NCT04579133
Status: TERMINATED
Last Update Posted: 2021-06-16
First Post: 2020-10-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Sponsor: Latin American Cooperative Oncology Group
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Bladder Cancer View
None Urothelial Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Bladder neoplasms View
None Bladder Cancer View
None Immunotherapy View